



Evidence-based Recommendations on the Implementation of Shared Decision Making in Multiple Myeloma

Jolien Broekmans¹, Elise Schoefs¹, Charlotte Verbeke¹, Silène ten Seldam², Katie Joyner², Kate Morgan², Eilidh Duncan², Varda Shoham³, Ariel Aviv⁴, Anneleen Vanhellemont⁵, Michel Delforge⁵, Isabelle Huys¹

¹ Clinical Pharmacology and Pharmacotherapy, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven (Belgium)

² Myeloma Patients Europe, Brussels, Belgium

³ AMEN association, Kiron, Israel

⁴ Department of Hematology, Ha'Emek medical center, Afula, Israel

⁵ Department of Hematology, University Hospital Leuven, Leuven, Belgium

Background

Shared Decision Making (**SDM**) is vital in oncology, but its **application** in Multiple Myeloma (MM) **clinical practice** is **not well studied** across different countries. We conducted interviews and surveys with patients and healthcare providers (HCPs) to identify **key factors influencing SDM** and **barriers** to its **effective implementation**. This study offers **actionable solutions** and **recommendations** to enhance SDM integration into MM care.

Objective

To provide evidence-based recommendations to **optimize patient involvement** and **enhance the implementation** of **SDM** in MM care across Europe.

